- Home
- NLSP vs CYCN Comparison
NLSP vs CYCN Comparison
Compare NLSP & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- CYCN
- Stock Information
- Founded
- NLSP 2015
- CYCN 2018
- Country
- NLSP Switzerland
- CYCN United States
- Employees
- NLSP N/A
- CYCN N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- CYCN Health Care
- Exchange
- NLSP Nasdaq
- CYCN Nasdaq
- Market Cap
- NLSP 5.8M
- CYCN 6.5M
- IPO Year
- NLSP 2021
- CYCN N/A
- Fundamental
- Price
- NLSP $1.62
- CYCN $3.04
- Analyst Decision
- NLSP
- CYCN
- Analyst Count
- NLSP 0
- CYCN 0
- Target Price
- NLSP N/A
- CYCN N/A
- AVG Volume (30 Days)
- NLSP 26.4K
- CYCN 16.1K
- Earning Date
- NLSP 05-27-2025
- CYCN 05-23-2025
- Dividend Yield
- NLSP N/A
- CYCN N/A
- EPS Growth
- NLSP N/A
- CYCN N/A
- EPS
- NLSP N/A
- CYCN N/A
- Revenue
- NLSP N/A
- CYCN $2,081,000.00
- Revenue This Year
- NLSP N/A
- CYCN N/A
- Revenue Next Year
- NLSP N/A
- CYCN N/A
- P/E Ratio
- NLSP N/A
- CYCN N/A
- Revenue Growth
- NLSP N/A
- CYCN N/A
- 52 Week Low
- NLSP $1.30
- CYCN $1.27
- 52 Week High
- NLSP $18.40
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- NLSP 53.77
- CYCN 50.15
- Support Level
- NLSP $1.58
- CYCN $2.83
- Resistance Level
- NLSP $1.75
- CYCN $3.34
- Average True Range (ATR)
- NLSP 0.10
- CYCN 0.32
- MACD
- NLSP 0.01
- CYCN -0.04
- Stochastic Oscillator
- NLSP 55.73
- CYCN 22.68
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.